Main clinical characteristics and histological features of 34 BI-ALCL patients
| No. . | Age, y . | BI-ALCL histological subtype (T component of MD Anderson TNM staging) . | Implant characteristics . | Ann Arbor staging . | Therapy (implant removal/CT/RT) . | Overall survival (mo) (outcome NED/DOD/DOC) . | T-cell clone (% tumor cells per sample) . | Exome sequencing by WES/TDS . | ||
|---|---|---|---|---|---|---|---|---|---|---|
| No. of implant surgeries prior to BI-ALCL diagnosis (reason for implant) . | ≥1 macrotextured implant . | Delay from the last implant to Bi-ALCL diagnosis (delay from first implant), y . | ||||||||
| 2 | 42 | In situ (T1) | 2 (cosmetic) | Yes | 10.5 (20) | I | Implant removal + RT | 56.48 (NED) | Yes (≤20) | WES |
| 5 | 54 | In situ (T1) | NA (cosmetic) | NA | 9 (NA) | IE | NA | NA | NA (20-50) | WES |
| 6 | 62 | In situ (T1) | 2 (breast carcinoma) | Yes | 0.26 (17) | IV | Implant removal | 55.59 (NED) | Yes (>50) | WES |
| 7 | 76 | In situ (T1) | 1 (breast carcinoma) | Yes | 14.23 | I | Implant removal | 44.91 (NED) | Yes (≤20) | WES + TDS |
| 8 | 43 | In situ (T1) | 1 (breast carcinoma) | Yes | 6.7 | I | Implant removal | 42.81 (NED) | Yes (20-50) | WES + TDS |
| 10 | 61 | Tumor type (T4) | 4 (cosmetic) | Yes | 7.2 (17) | IV | Implant removal + CT1 | 77.24 (NED) | Yes (>50) | TDS |
| 11 | 54 | Tumor type (T4) | NA (cosmetic) | Yes | 3 (NA) | II | NA | NA | Yes (>50) | TDS |
| 13 | 82 | Tumor type (T4) | 1 (breast carcinoma) | Yes | 6.96 | IV | Implant removal + CT1 | 10.45 (DOD) | Yes (>50) | WES |
| 14 | 80 | Tumor type (T3) | NA (cosmetic) | Yes | 8 | IE | Implant removal + CT1 | 3 (NED) | NA (>50) | TDS |
| 15 | 50 | In situ (T1) | NA (cosmetic) | Yes | 8 | IE | Implant removal | NA | Yes (≤20) | TDS |
| 16 | 77 | In situ (T1) | 3 (breast carcinoma) | Yes | 1.23 (NA) | I | Implant removal + CT2 | 60.29 (NED) | NA (≤20) | WES |
| 17 | 74 | Tumor type (T4) | 2 (breast carcinoma) | Yes | 8.12 (NA) | IV | Implant removal + CT1 | 44.88 (NED) | Yes (≤20) | WES |
| 18 | 75 | In situ (T1) | 5 (breast carcinoma) | Yes | 1.27 (NA) | IV | Implant removal + CT1 | 16.39 (DOD) | NA (≤20) | TDS |
| 19 | 57 | Tumor type (T4) | 2 (breast carcinoma) | Yes | 7.57 (NA) | IV | NA | 3.71 (DOC) | Yes (20-50) | WES + TDS |
| 21 | 62 | In situ (T1) | 1 (breast carcinoma) | Yes | 9.37 | I | Implant removal | 27.73 (NED) | Yes (≤20) | WES + TDS |
| 22 | 39 | In situ (T1) | 1 (cosmetic) | Yes | 6.48 | I | Implant removal | 23.95 (NED) | NA (20-50) | WES |
| 24 | 62 | In situ (T1) | 2 (breast carcinoma) | NA | 4.57 (NA) | I | Implant removal + CT | 30.39 (NED) | NA (≤20) | WES + TDS |
| 26 | 54 | In situ (T1) | 1 (cosmetic) | Yes | 9.88 | I | Implant removal | 27.17 (NED) | NA (≤20) | TDS |
| 28 | 66 | Tumor type (T2) | 2 (breast carcinoma) | Yes | 5.36 (NA) | II | Implant removal + CT | 22.01 (NED) | No (≤20) | WES + TDS |
| 29 | 44 | Tumor type (T2) | 1 (cosmetic) | Yes | 8.07 | I | Implant removal | 22.64 (NED) | No (20-50) | WES + TDS |
| 30 | 54 | Tumor type (T2) | 2 (breast carcinoma) | Yes | 3.6 (NA) | I | Implant removal + CT | 25.26 (NED) | No (>50) | WES + TDS |
| 31 | 54 | In situ (T1) | 1 (cosmetic) | Yes | 5.11 | IV | Implant removal | 24.67 (NED) | Yes (≤20) | TDS |
| 32 | 65 | In situ (T1) | 3 (cosmetic) | Yes | 4.25 (NA) | I | Implant removal | 21.32 (NED) | Yes (≤20) | WES |
| 33 | 40 | Tumor type (T3) | 1 (cosmetic) | Yes | 10.12 | IV | Implant removal + CT | 19.22 (NED) | Yes (>50) | WES + TDS |
| 34 | 50 | Tumor type (T3) | 1 (cosmetic) | Yes | 9.85 | I | Implant removal | 15.74 (NED) | Yes (>50) | WES + TDS |
| 35 | 43 | Tumor type (Tx) | 1 (cosmetic) | NA | 12.31 | IV | Implant removal + CT | 23.49 (NED) | Yes (>50) | TDS |
| 36 | 72 | In situ (T1) | 1 (cosmetic) | Yes | 22.77y | I | Implant removal | 11.76 (NED) | Yes (>50) | TDS |
| 37 | 63 | Tumor type (T3) | 1 (breast carcinoma) | Yes | 8.74y | I | CT | 7.75 (DOD) | NA (>50) | WES |
| 38 | 55 | In situ (T1) | 3 (breast carcinoma) | Yes | 5.31 (NA) | I | Implant removal | 13.11 (NED) | Yes (>50) | TDS |
| 42 | 48 | In situ (T1) | 2 (cosmetic) | Yes | 4.88 (NA) | I | Implant removal | 13.54 (NED) | Yes (>50) | WES + TDS |
| 48 | 65 | Tumor type (T4) | 3 (cosmetic) | Yes | 0.5 (NA) | I | Implant removal | 7.66 (NED) | Yes (≤20) | TDS |
| 50 | 58 | In situ (T1) | 2 (cosmetic) | Yes | 1.89 (11) | IV | Implant removal | NA | No (≤20) | TDS |
| Bel1 | 59 | In situ (T1) | 2 (NA) | Yes | 8 (NA) | I | Implant removal | 18 (NED) | NA (>50) | WES |
| Bel2 | 47 | Tumor type (T2) | 2 (NA) | Yes | 6 (13) | NA | Implant removal | 22 (NED) | Yes (20-50) | WES + TDS |
| No. . | Age, y . | BI-ALCL histological subtype (T component of MD Anderson TNM staging) . | Implant characteristics . | Ann Arbor staging . | Therapy (implant removal/CT/RT) . | Overall survival (mo) (outcome NED/DOD/DOC) . | T-cell clone (% tumor cells per sample) . | Exome sequencing by WES/TDS . | ||
|---|---|---|---|---|---|---|---|---|---|---|
| No. of implant surgeries prior to BI-ALCL diagnosis (reason for implant) . | ≥1 macrotextured implant . | Delay from the last implant to Bi-ALCL diagnosis (delay from first implant), y . | ||||||||
| 2 | 42 | In situ (T1) | 2 (cosmetic) | Yes | 10.5 (20) | I | Implant removal + RT | 56.48 (NED) | Yes (≤20) | WES |
| 5 | 54 | In situ (T1) | NA (cosmetic) | NA | 9 (NA) | IE | NA | NA | NA (20-50) | WES |
| 6 | 62 | In situ (T1) | 2 (breast carcinoma) | Yes | 0.26 (17) | IV | Implant removal | 55.59 (NED) | Yes (>50) | WES |
| 7 | 76 | In situ (T1) | 1 (breast carcinoma) | Yes | 14.23 | I | Implant removal | 44.91 (NED) | Yes (≤20) | WES + TDS |
| 8 | 43 | In situ (T1) | 1 (breast carcinoma) | Yes | 6.7 | I | Implant removal | 42.81 (NED) | Yes (20-50) | WES + TDS |
| 10 | 61 | Tumor type (T4) | 4 (cosmetic) | Yes | 7.2 (17) | IV | Implant removal + CT1 | 77.24 (NED) | Yes (>50) | TDS |
| 11 | 54 | Tumor type (T4) | NA (cosmetic) | Yes | 3 (NA) | II | NA | NA | Yes (>50) | TDS |
| 13 | 82 | Tumor type (T4) | 1 (breast carcinoma) | Yes | 6.96 | IV | Implant removal + CT1 | 10.45 (DOD) | Yes (>50) | WES |
| 14 | 80 | Tumor type (T3) | NA (cosmetic) | Yes | 8 | IE | Implant removal + CT1 | 3 (NED) | NA (>50) | TDS |
| 15 | 50 | In situ (T1) | NA (cosmetic) | Yes | 8 | IE | Implant removal | NA | Yes (≤20) | TDS |
| 16 | 77 | In situ (T1) | 3 (breast carcinoma) | Yes | 1.23 (NA) | I | Implant removal + CT2 | 60.29 (NED) | NA (≤20) | WES |
| 17 | 74 | Tumor type (T4) | 2 (breast carcinoma) | Yes | 8.12 (NA) | IV | Implant removal + CT1 | 44.88 (NED) | Yes (≤20) | WES |
| 18 | 75 | In situ (T1) | 5 (breast carcinoma) | Yes | 1.27 (NA) | IV | Implant removal + CT1 | 16.39 (DOD) | NA (≤20) | TDS |
| 19 | 57 | Tumor type (T4) | 2 (breast carcinoma) | Yes | 7.57 (NA) | IV | NA | 3.71 (DOC) | Yes (20-50) | WES + TDS |
| 21 | 62 | In situ (T1) | 1 (breast carcinoma) | Yes | 9.37 | I | Implant removal | 27.73 (NED) | Yes (≤20) | WES + TDS |
| 22 | 39 | In situ (T1) | 1 (cosmetic) | Yes | 6.48 | I | Implant removal | 23.95 (NED) | NA (20-50) | WES |
| 24 | 62 | In situ (T1) | 2 (breast carcinoma) | NA | 4.57 (NA) | I | Implant removal + CT | 30.39 (NED) | NA (≤20) | WES + TDS |
| 26 | 54 | In situ (T1) | 1 (cosmetic) | Yes | 9.88 | I | Implant removal | 27.17 (NED) | NA (≤20) | TDS |
| 28 | 66 | Tumor type (T2) | 2 (breast carcinoma) | Yes | 5.36 (NA) | II | Implant removal + CT | 22.01 (NED) | No (≤20) | WES + TDS |
| 29 | 44 | Tumor type (T2) | 1 (cosmetic) | Yes | 8.07 | I | Implant removal | 22.64 (NED) | No (20-50) | WES + TDS |
| 30 | 54 | Tumor type (T2) | 2 (breast carcinoma) | Yes | 3.6 (NA) | I | Implant removal + CT | 25.26 (NED) | No (>50) | WES + TDS |
| 31 | 54 | In situ (T1) | 1 (cosmetic) | Yes | 5.11 | IV | Implant removal | 24.67 (NED) | Yes (≤20) | TDS |
| 32 | 65 | In situ (T1) | 3 (cosmetic) | Yes | 4.25 (NA) | I | Implant removal | 21.32 (NED) | Yes (≤20) | WES |
| 33 | 40 | Tumor type (T3) | 1 (cosmetic) | Yes | 10.12 | IV | Implant removal + CT | 19.22 (NED) | Yes (>50) | WES + TDS |
| 34 | 50 | Tumor type (T3) | 1 (cosmetic) | Yes | 9.85 | I | Implant removal | 15.74 (NED) | Yes (>50) | WES + TDS |
| 35 | 43 | Tumor type (Tx) | 1 (cosmetic) | NA | 12.31 | IV | Implant removal + CT | 23.49 (NED) | Yes (>50) | TDS |
| 36 | 72 | In situ (T1) | 1 (cosmetic) | Yes | 22.77y | I | Implant removal | 11.76 (NED) | Yes (>50) | TDS |
| 37 | 63 | Tumor type (T3) | 1 (breast carcinoma) | Yes | 8.74y | I | CT | 7.75 (DOD) | NA (>50) | WES |
| 38 | 55 | In situ (T1) | 3 (breast carcinoma) | Yes | 5.31 (NA) | I | Implant removal | 13.11 (NED) | Yes (>50) | TDS |
| 42 | 48 | In situ (T1) | 2 (cosmetic) | Yes | 4.88 (NA) | I | Implant removal | 13.54 (NED) | Yes (>50) | WES + TDS |
| 48 | 65 | Tumor type (T4) | 3 (cosmetic) | Yes | 0.5 (NA) | I | Implant removal | 7.66 (NED) | Yes (≤20) | TDS |
| 50 | 58 | In situ (T1) | 2 (cosmetic) | Yes | 1.89 (11) | IV | Implant removal | NA | No (≤20) | TDS |
| Bel1 | 59 | In situ (T1) | 2 (NA) | Yes | 8 (NA) | I | Implant removal | 18 (NED) | NA (>50) | WES |
| Bel2 | 47 | Tumor type (T2) | 2 (NA) | Yes | 6 (13) | NA | Implant removal | 22 (NED) | Yes (20-50) | WES + TDS |
CT, chemotherapy not specified; CT1, cyclophosphamide, Adriamycin, vincristine, and prednisone (6 cures) (CHOP or CHOP-like); CT2, dexamethasone, high-dose aracytine, oxaliplatin (DHAOX); DOC, dead from other cause (breast carcinoma); DOD, dead of disease; NA, not available; NED, no evidence of disease; RT, radiotherapy.